News

Indian drug maker cuts price of three cancer drugs by between 50% and 63%

BMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e7786 (Published 16 November 2012) Cite this as: BMJ 2012;345:e7786
  1. Meera Kay
  1. 1Bangalore

Taking a step forward in making drugs “affordable and accessible,” Cipla, one of the largest Indian drug makers, recently announced cuts of between 50% and 63% in the price of three cancer drugs—erlotinib, docetaxel, and capecitabine.1

The announcement comes six months after the first such announcement by Cipla, when it slashed the price of three major anti-cancer drugs—sorafenib, gefitinib, and temozolomide—by 76%, cutting across the drug pricing barrier in India.2

“Following the …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe